 |
SYDNEY, May 8, 2019 /PRNewswire/ -- This World Ovarian Cancer Day, Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) calls for greater awareness of what is the most lethal gynaecological cancer in the US.
In 2019, around 22,530 women will receive a new diagnosis of ovarian cancer[1] while the disease has one of the lowest survival rates of all female cancers, with only 46.5% of patients surviving five years post diagnosis[2].
Kazia's CEO, Dr James Garner said, "In 2019, more than 13,000 women will die from ovarian cancer in the US, so we are urging all women to understand all of the major signs and symptoms of ovarian cancer and seek regular check-ups with their doctors if feeling unwell.
The four major symptoms of ovarian cancer are feeling full after eating a small amount, increased abdominal size or persistent bloating, abdominal or pelvic pain and the need to urinate urgently or often. Given these are symptoms common to other easily explained conditions means that patients present for diagnosis late."
The most commonly reported symptoms are[3]:
Other signs to watch out for include[4]:
Sally Goers Fox was diagnosed with ovarian cancer in 2005. She was misdiagnosed twice by gynaecologists before her family doctor diagnosed her and she went on to be treated successfully. She says, looking back, she had ovarian cancer symptoms for around 18 months.
"There needs to be much more education about it. I am well-educated, well read and I am an 'on top of my medical stuff kind of person'. I also had breast cancer at an early age … so I was on high alert. I didn't know that I had a lot of the classic symptoms for ovarian cancer. I just didn't know.
"[My advice to women is] to dig deeper in terms of learning about the symptoms. If you want to arm yourself in the best way, learn a lot more about the symptoms than just the typical list that you get."
Kazia Therapeutics is developing a treatment called Cantrixil for ovarian cancer, which is currently in phase I human trials in hospitals across Australia and the United States.
The Company recently reported early efficacy results from Part A of the phase I study. Of nine patients evaluable for efficacy, five (56%) achieved stable disease after two cycles of Cantrixil monotherapy. One of these five patients subsequently achieved a partial response when Cantrixil was administered with chemotherapy, as intended per protocol.
Cantrixil may provide a new treatment option for women with later-stage ovarian cancer, who received limited benefit from existing chemotherapy. Depending on clinical trial results, Cantrixil could prolong survival rates for women with ovarian cancer by targeting chemotherapy-resistant tumour-initiating cells that are thought to be responsible for disease relapse.
For more information on Kazia Therapeutics or Cantrixil, please visit: www.kaziatherapeutics.com
[1] Source: American Cancer Society: https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html [2] Source: Ovarian Cancer Research Alliance: https://ocrahope.org/patients/about-ovarian-cancer/statistics/ [3] Source: American Cancer Society: https://www.cancer.org/cancer/ovarian-cancer/detection-diagnosis-staging/signs-and-symptoms.html. [4] Source: American Cancer Society: https://www.cancer.org/cancer/ovarian-cancer/detection-diagnosis-staging/signs-and-symptoms.html. |
View original content to download multimedia:http://www.prnewswire.com/news-releases/kazia-calls-for-greater-awareness-of-the-deadliest-gynecological-cancer-in-the-us-300846138.html